Lytix Biopharma (OB:LYTIX) - Share price, News & Analysis

LYTIX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

LYTIX Stock Overview

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.

Risk Analysis

Makes less than USD$1m in revenue (NOK6M)

Does not have a meaningful market cap (NOK381M)

Lytix Biopharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lytix Biopharma
Historical stock prices
Current Share Price	kr9.50
52 Week High	kr21.50
52 Week Low	kr9.00
Beta	0
1 Month Change	-9.52%
3 Month Change	-19.49%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-48.93%

Recent News & Updates

Jan 25

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Sep 14

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

	LYTIX	NO Biotechs	NO Market
7D	-5.0%	0.7%	3.5%
1Y	n/a	-47.0%	16.1%

Return vs Industry: Insufficient data to determine how LYTIX performed against the Norwegian Biotechs industry.

Return vs Market: Insufficient data to determine how LYTIX performed against the Norwegian Market.

Price Volatility

Is LYTIX's price volatile compared to industry and market?
LYTIX volatility
LYTIX Average Weekly Movement	9.0%
Biotechs Industry Average Movement	8.6%
Market Average Movement	7.5%
10% most volatile stocks in NO Market	12.6%
10% least volatile stocks in NO Market	4.3%

Stable Share Price: LYTIX is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: LYTIX's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2003	8	Oystein Rekdal	https://www.lytixbiopharma.com

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.

Lytix Biopharma Fundamentals Summary

How do Lytix Biopharma's earnings and revenue compare to its market cap?
LYTIX fundamental statistics
Market Cap	kr380.65m
Earnings (TTM)	-kr48.05m
Revenue (TTM)	kr6.35m

60.0x

P/S Ratio

-7.9x

P/E Ratio

Is LYTIX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
LYTIX income statement (TTM)
Revenue	kr6.35m
Cost of Revenue	kr0
Gross Profit	kr6.35m
Other Expenses	kr54.40m
Earnings	-kr48.05m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)	-1.20
Gross Margin	100.00%
Net Profit Margin	-756.80%
Debt/Equity Ratio	0.0%

How did LYTIX perform over the long term?

See historical performance and comparison

Valuation

Is Lytix Biopharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

2.01x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: LYTIX is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: LYTIX is unprofitable, so we can't compare its PE Ratio to the Norwegian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LYTIX's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: LYTIX is good value based on its PB Ratio (2x) compared to the NO Biotechs industry average (4x).

Future Growth

How is Lytix Biopharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

76.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lytix Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Lytix Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

12.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LYTIX is currently unprofitable.

Growing Profit Margin: LYTIX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: LYTIX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.7% per year.

Accelerating Growth: Unable to compare LYTIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LYTIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: LYTIX has a negative Return on Equity (-25.34%), as it is currently unprofitable.

Financial Health

How is Lytix Biopharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LYTIX's short term assets (NOK203.0M) exceed its short term liabilities (NOK13.3M).

Long Term Liabilities: LYTIX has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: LYTIX is debt free.

Reducing Debt: LYTIX has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LYTIX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: LYTIX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.2% each year

Dividend

What is Lytix Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LYTIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LYTIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LYTIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LYTIX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LYTIX has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure

CEO

Oystein Rekdal

19.33yrs

Tenure

kr7,331,000

Compensation

Dr. Oystein Rekdal, Ph.D. co-founded Lytix Biopharma AS in 2003 and serves as its Chief Executive Officer since September 11, 2019. Dr. Rekdal was Chief Scientific Officer of Lytix Biopharma AS since April...

CEO Compensation Analysis

Compensation vs Market: Oystein's total compensation ($USD747.80K) is above average for companies of similar size in the Norwegian market ($USD331.54K).

Compensation vs Earnings: Oystein's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: LYTIX's management team is considered experienced (3 years average tenure).

Board Members

Experienced Board: LYTIX's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: LYTIX only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2022/05/18 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31